Priyamvada Maitre, Radiation Oncologist at Tata Memorial Centre, reshared a recent article on X by Vedang Murthy, Professor of GU-Radiation Oncology at Tata Memorial Centre, Mumbai, adding:
“2025 begins with IJROBP – The Red Journal.
Elective pelvic SBRT in high-risk prostate cancer.
Pooled data from SHARP consortium U.S, India, and Canada.
25Gy/5 to pelvic nodes to 98% pelvic control.
Good news for global SBRT trials using nodal 25/5 U.S, U.K, India, Canada, Netherland and China.”
Authors: Vedang Murthy, Indranil Mallick, Priyamvada Maitre, Gargee Mulye, Moses Arunsingh, Luca Valle, Michael Steinberg, Thomas Kennedy, Andrew Loblaw and Amar U Kishan
Quoting Vedang Murthy’s post:
“With the new year, comes new insight.
Is 25Gy/5 enough for prophylactic nodal RT in high-risk Prostate Cancer?
Borrowed from rectal cancer protocols, it has never been validated for prostate SBRT—until now.
The SHARP consortium offers insights.”
For more updates, follow OncoDaily.
